Biotech mergers and acquisitions reached $78 billion in the first half of 2026, surpassing the entire 2025 total of $42 billion, driven by several large deals over $5 billion. Despite strong structural drivers like patent expirations and cash reserves in big pharma, the pool of buyers is shrinking as top acquirers have spent much of their capacity. This limits the pace of future deals, though companies like Merck, Novo Nordisk, and AstraZeneca still have firepower. RBC Capital Markets expects M&A activity to continue but at a slower rate than the recent surge.
The FDA has approved Bixlenvo, a once-daily HIV pill from Gilead that combines bictegravir and lenacapavir to simplify treatment for patients with suppressed virus but complex regimens. It targets those who cannot use current single-pill options due ...
The VanEck Biotech ETF (BBH) is recommended as a Buy due to its focused exposure to top biotech companies like Amgen, Gilead, and Vertex, which are entering a new growth phase. These firms support capital growth through diverse drug pipelines, strong...
